What Questcor Investors Absolutely Must Watch

When investing in biotech stocks, investors have to be aware of the numerous risks involved. While binary events such as clinical trial data releases or FDA approval decisions are the most notable, even companies with approved and commercialized drugs can carry serious risks and exposures.

One example of this is Questcor Pharmaceuticals (NASDAQ: QCOR  ) . Sales of its top drug, Acthar, are growing at incredible rates, but the stock's valuation has dropped considerably. In the following video, Brenton Flynn runs through the situation and highlights the key areas investors need to watch with this stock.

If you want more insight on Questcor, we highlight the high-profile issues facing the company inside our brand new premium research report. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.


Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 30, 2013, at 4:19 PM, drdonrs wrote:

    Your articles, and I use the word loosely, are an out and out attempt to peddle your commercial product. Your so called premium research reports are anything but. When you latch onto a particular pathway as relates to a particular stock, such as QCOR, it is quite obvious that you have a goal in sight...to sell reports by attempting to make them sound like new revelations. I have read some of the information that you seem to produce regarding QCOR and it is inevitably filled with innuendos, mistruths and a general line taken by a pseudo subtle short. Perhaps you should start writing copy for Andrew Left, a not so subtle short. My Rx for you is to bone up on the mechanisms of Rx reimbursement for medical insurance plans and the appeal processes that are in place. You might then not be so surprised when the stock breaks out to the upside after trading sideways for this period of time.

  • Report this Comment On January 31, 2013, at 9:13 AM, Grayhouse wrote:

    Maybe you should brush up on your MS knowledge. Acthar (thank you for now pronouncing it correctly) is not a Disease Modifier such as Gilenya, Aubagio or BG-12. How far along someone's disease is, has nothing to do when Acthar is used. It does not compete with these drugs. It is used in conjunction.

    Secondly, your warning of a potential generic, "possibly years and years away". Seriously?! Every product is subject to generic "years and years away". That comment is just embarrassing!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2225232, ~/Articles/ArticleHandler.aspx, 9/1/2014 7:29:48 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement